Atyr Pharma Inc. (LIFE) Trading Down 1.7%
Atyr Pharma Inc. (NASDAQ:LIFE) shares fell 1.7% during mid-day trading on Monday . The stock traded as low as $2.88 and last traded at $2.90, with a volume of 217,900 shares. The stock had previously closed at $2.95.
Several brokerages have recently issued reports on LIFE. Citigroup Inc. raised their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, August 16th. Zacks Investment Research upgraded shares of Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Tuesday, August 16th. JPMorgan Chase & Co. cut their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Finally, BMO Capital Markets restated a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Atyr Pharma has an average rating of “Hold” and a consensus price target of $6.00.
The company has a 50 day moving average price of $3.11 and a 200 day moving average price of $3.61. The firm’s market capitalization is $68.78 million.
Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.06. On average, equities research analysts expect that Atyr Pharma Inc. will post ($2.56) EPS for the current fiscal year.
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.